3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
2
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Breast Neoplasms
62
Carcinoma, Non-Small-Cell Lung
45
Triple Negative Breast Neoplasms
24
Ovarian Neoplasms
20
Fallopian Tube Neoplasms
17
Neoplasm Metastasis
16
Lung Neoplasms
16
Endometrial Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Stomach Neoplasms
12
Esophageal Neoplasms
10
Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Esophageal Squamous Cell Carcinoma
8
Colorectal Neoplasms
7
Inflammatory Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma
6
Uterine Cervical Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Melanoma
4
Carcinoma, Transitional Cell
4
Carcinoma, Squamous Cell
4
Adenocarcinoma Of Esophagus
4
Urinary Bladder Neoplasms
3
Peritoneal Neoplasms
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Lung Diseases
3
Interventions
selpercatinib
2
durvalumab
2
Paclitaxel
2
Carboplatin
2
ceralasertib
1
atezolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Respiratory Tract Neoplasms
×
Paclitaxel
×
Clear all
NCT04564157
2026-05-05
NADIM-ADJUVANT
Fundación GECP
Phase 3
Active not recruiting
210 enrolled
NCT04776447
2025-04-09
APOLO
Fundación GECP
Phase 2
Active not recruiting
38 enrolled